B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $110 to $125.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.